What is Medifast's SG&A?

Medifast (MED) reported SG&A of $55.05M in Q1 2026.

How has Medifast's SG&A changed year-over-year?

Medifast's SG&A decreased by 35.6% year-over-year, from $85.51M to $55.05M.

What is the long-term trend for Medifast's SG&A?

Over 4 years (2021 to 2025), Medifast's SG&A has grown at a -24.9% compound annual growth rate (CAGR), from $911.36M to $289.4M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Medifast MED SG&A

SG&A at other companies

Eli LillyLLY

$2.93B+18.9%

WW International, Inc.WW

$48.08M+35.0%

Lifevantage CorporationLFVN

$13.87M-18.8%

Other financials

Income statement

See full

Revenue$76.0M-34.3%

Gross profit$51.8M-38.6%

Operating income-$3.3M-161%

Net income-$2.1M-175%

EPS (diluted)-$0.19-171%

Balance sheet

See full

Cash & equivalents$71.5M-22.0%

Total debt$16.1M+10.2%

Total equity$197.7M-6.3%

Total assets$252.0M-10.0%

Cash flow

See full

Operating cash flow$260.0K-92.4%

CapEx$1.1M-28.0%

Free cash flow-$836.0K-144%

Valuation

See full

Market cap$121.87M-17.4%

Enterprise value$66.44M+12.8%

P/S0.4×0.0×

Profitability

See full

Gross margin70.1%-3.8pp

Operating margin-4.7%-7.0pp

Net margin-5.8%-8.1pp

FCF margin5%-9.3pp

Returns & leverage

See full

Return on equity-9.8%-20.1pp

Debt / equity0.1×0.0×

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Medifast in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medifast's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Medifast's SG&A?: Medifast (MED) reported SG&A of $55.05M in Q1 2026.
How has Medifast's SG&A changed year-over-year?: Medifast's SG&A decreased by 35.6% year-over-year, from $85.51M to $55.05M.
What is the long-term trend for Medifast's SG&A?: Over 4 years (2021 to 2025), Medifast's SG&A has grown at a -24.9% compound annual growth rate (CAGR), from $911.36M to $289.4M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.